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ABSTRACT
Colorectal cancer refers to the cancer that occurs in the colon and rectum. It has been established as the third most 
common cancer and the forth one in causing worldwide mortality. Cancer caused by the mutation of several genes that 
usually involved in the regulation of cell proliferation, growth and cell death. The mutation that leads to abnormal 
function of genes, either in enabling the genes to gain or loss of function was termed as driver mutation and the genes 
with driver mutation ability was termed as driver genes. The identification of driver genes provides insight on mechanistic 
process of cancer development where this information can be used to further understand their mode of action for causing 
dysregulation in signaling pathways. In this study, two bioinformatic tools, i.e. CGI and iCAGES were used to predict 
potential driver genes from the genome of eight colorectal cancer patients with annotated variants datasets. 44 unique 
driver genes and 21 pathways have been identified; such as p53 signaling, PI3K-AKT, Endocrine resistance, MAPK and 
cell cycle pathways. The identification of these pathways can lead to the identification of potential drugs targeting these 
pathways.
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ABSTRAK
Kanser kolorektum adalah kanser yang berlaku pada kolon dan juga rektum. Ia merupakan kanser ketiga yang paling 
kerap dilaporkan serta yang keempat menjadi punca kematian tertinggi di seluruh dunia. Kanser berlaku disebabkan 
oleh mutasi daripada gen tertentu yang terlibat di dalam pengawalaturan proliferasi, pertumbuhan dan kematian sel. 
Mutasi yang mencetuskan perubahan pada fungsi gen sama ada meningkatkan atau menghilangkan fungsinya dikenali 
sebagai mutasi pemandu, manakala gen yang mempunyai mutasi pemandu dikenali sebagai gen pemandu kanser. 
Pengenalpastian gen pemandu membolehkan mekanisme pembentukan kanser dapat dikenal pasti melalui peranannya 
dalam pengawalaturan tapak jalan. Dalam kajian ini, dua perisian bioinformatik iaitu CGI dan iCAGES telah digunakan 
untuk mengenal pasti calon gen pemandu daripada set data varian yang telah dianotasi daripada genom lapan pesakit 
kanser kolorektum. Sebanyak 44 gen pemandu dan 21 tapak jalan terlibat telah dikenal pasti; antaranya adalah tapak 
jalan pengisyaratan p53, PI3K-AKT, rintangan endokrin dan MAPK. Kesemua tapak jalan ini berpotensi untuk dijadikan 
sasaran terapi.
Kata kunci: Analisis tapak jalan; gen pemandu kanser; kanser kolorektum; perubatan jitu
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer involving 2.4 million people per year worldwide. 
According to the age-standardized rate, the incidence of 
colorectal cancer in Malaysia showed higher occurrence in 
men by 20.9 cases per 100,000 compared to in women at 
16.8 per 100,000 populations (Chye et al. 2008). Majority 
of the cases occurred in Chinese ethnic followed by the 
Malays and Indians (Radzi et al. 2016). Dietary habit has 
been listed as a main factor that affects intestinal macro and 
microenvironment. Consumption of food that affects the 
intestinal lining gave rise to the development of polyps. It 
was due to the harmful chemicals that are able to penetrate 
the cells and disturb genome stability by a process known 
as mutation (Kanner 2007; O’Keefe 2016; Ryan-Harshman 
& Aldoori 2007). The examples of bad dietary habit include 
consumption of carcinogenic foods, lack of dietary fiber 
in the diet that lead to the intestinal bleeding as well as a 
disturbance to the microbiome environment and probiotic 
metabolisms (Louis et al. 2014). 
 Consumption of food high in fiber enables gut 
microbiota to produce short-chain fatty acid such as 
butyrate during fermentation. Butyrate has an anti-
inflammatory and antineoplastic properties; and it can 
also provide the best energy source for colonocytes. 
Therefore, the risk of intestinal bleeding will be reduced 
as inflammation is suppressed by the anti-inflammatory 
substances produced by gut microbiota. Imbalance diet 
such as high consumption of protein and fat will produce 
substances with carcinogenic effects such as branched 
fatty acids that may induce inflammation and hydrogen 
sulfide that could cause DNA damage and lead to mutation 
if the repair mechanism is disrupted (O’Keefe 2016). 
These mutations may eventually affect the genes that are 
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necessary to regulate cellular growth and to maintain the 
balance of cell proliferation.
 Cancer driver genes are defined as genes that provide 
selective advantage for the cell to grow more rapidly 
as the proliferation and death-escaping characteristics 
of the cell are enhanced. These properties enable cells 
to grow more rapidly than their neighbouring cell in 
a specific condition and environment (Tokheim et al. 
2016). Cancer driver genes such as APC (adenomatous 
polyposis coli) gene plays a critical role in regulating Wnt 
signaling pathway that responsible for cell proliferation. 
APC forms a destruction complex with several other 
proteins to inhibit ß-catenin, a protein that activates 
Wnt signaling and preventing the cells to proliferate 
continuously. Mutation in APC may affect its function to 
perform destruction complex and unable to control cell 
proliferation (Kwong & Dove 2009; Zhan et al. 2017). 
Driver genes can be mutated at both protein coding and 
non-coding regions but more commonly at the protein 
coding region. This mutation causes abnormal function 
of the genes and is known as driver mutation (Foo et al. 
2015). The term ‘driver’ is introduced to distinguish it 
from a passenger gene that does not contribute to any 
abnormal cell growth. Passenger genes could be any 
genes or recorded as driver genes in TCGA database, 
however does not carry any driver mutation that affect 
their structure and function (Marx 2014). 
 Identification of cancer driver genes is one of the 
important aspects in whole genome sequencing projects. 
Two prominent consortiums working on the collection 
of cancer genes data are Cancer Genome Atlas (TCGA) 
and International Cancer Genome Consortium (ICGC). 
The top driver genes that currently reported contribute 
to colorectal carcinogenesis are APC, TP53 and KRAS. APC 
acts as tumor suppressor that form ‘destruction complex’ 
with Axin and GSK-3β to degrade β-Catenin in Wingless 
(Wnt) signaling pathway. Mutation which could lead 
to loss function of APC allows β-catenin keep acting as 
signal to promote cell proliferation through Wnt signaling 
pathway (Alberts 2008; Kwong & Dove 2009). TP53 is 
activated by cellular stresses including DNA damage and 
acts as tumor suppressor that bind to regulatory regions of 
downstream target genes to induce cell cycle arrest, DNA 
repair and apoptosis (Iacopetta et al. 2006). Inactivation 
of TP53 is associated with later stage in cancer as the role 
of TP53 as an important upstream key regulator to control 
the number of cancer cells through apoptosis become 
malfunction (Rivlin et al. 2011). Proto-oncogene is a 
gene that normally has a role in activating or continuing 
cell proliferation, growth and differentiation activity. 
Mutation in this type of genes could lead to gain of 
function and transform proto-oncogenes to new role in 
driving cancer known as oncogenes. Oncogene such as 
KRAS could drive the cancer through mutation at specific 
binding sites. This could prevent KRAS to degrade and 
enable the pathways continuously run to induce cell 
growth and proliferation. 
 Precision medicine in cancer requires the information 
of cancer driver genes in order to perform specific therapy 
to target altered function of component in signaling 
pathways. Genes like KRAS has been targeted through 
biologic agents like cetuximab and panitumumab in 
clinical trials (Tan & Du 2012).
 Various bioinformatics tools for driver genes 
prediction have been developed to provide analysis 
tools for tumor sequencing project to distinguish driver 
and passenger genes; amongst other are SIFT (Sorting 
Intolerants from Tolerant) and Polyphen 2 (Polymorphism 
Phenotyping v2) (Adzhubei et al. 2015; Sim et al. 2012), 
HotNet2, MUFFINN (Mutations For Functional Impact on 
Network Neighbors) (Cho et al. 2016; Leiserson et al. 
2014) and MuSIC (Mutational Significance in Cancer) 
(Dees et al. 2012). Here, two computational methods were 
used, i.e. Integrated Cancer Genome Score (iCAGES) and 
Cancer Genome interpreter (CGI). Both tools allowed for 
a single patient-based data analysis in determining high 
confidence prediction on driver genes via a combination 
of different tools that use different concept of systematic 
approaches.
 iCAGES analyses the impact of variants using the 
scores obtained from eleven prediction tools that predict 
the impact of variants on the protein structure and 
function. Identification of cancer driver genes uses radial 
support vector machine (radial svm), a machine learning 
algorithm that combines all scores from the prediction 
tools. These tools were SIFT, PolyPhen 2, GERP++, 
Mutation Assessor, SiPhy, LRT, PhyloP, FATHMM, Mutation 
Tester, CADD and VEST. Driver gene prioritization unified 
radial SVM score with other bioinformatic tool known 
as Phenolyzer that predicts driver genes based on the 
oncogenicity of point coding mutation. Linear regression 
(LR) model is built to determine driver gene score with 
0.11 as binary cut off for suggested cancer driver genes. 
 CGI determine the characteristics of cancer driver 
genes through the classification of genes based on their 
tumorigenic mode (Oncogene or Tumor Suppressor). 
Functional impact according to types of mutation, and 
occurrence among human population. CGI search and 
match query variants with TCGA database of cancer 
genes. Variants with no matches in TCGA library will 
undergo protein affecting mutation (PAM) assessment by 
algorithm known as Oncodrive-MUT. Oncodrive-MUT was 
built based on the random forest machine learning and 
classification algorithm that separate driver and passenger 
genes mutation by 0.78 accuracy based on Matthews 
Correlation Coefficient. 
MATERIALS AND METHODS
DATA SOURCE
Variant annotated datasets (VCF) were obtained from eight 
patients (patient identification: C187, C194, C273, C373, 
C404, C414, C449, C474) involved in the CRC patient 
genome sequencing project led by UKM Medical Molecular 
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Medicine Institute (UMBI). Illumina Hiseq (30× coverage) 
was used for the sequencing and Gene Analysis Toolkit 
(GATK) was used in variant calling.
PREDICTION OF CRC DRIVER GENE USING  
BIOINFORMATICS TOOLS
Data were filtered by selecting all variants that occur at 
the exonic region as they are required as input in both 
tools. In iCAGES, the analysis was performed via http://
icages.wglab.org/ using hg19 as a reference genome. 
The required input format consists of the information on 
the chromosome, coordinates, references and alternate 
nucleotides. The output for the driver genes prediction 
consists of a list of genes with radial SVM score, funseq, 
cnv, phenolyzer and iCAGES gene score. As this analysis 
was focused on the nonsynonymous variants that occur at 
the coding region, the funseq and cnv scores were set at 0 
and not included in the driver genes prediction. Predicted 
driver genes with gene score more than 0.11 were selected 
for the comparison with CGI results. 
 CGI analysis was performed on https://www.
cancergenomeinterpreter.org and colon adenocarcinoma 
was selected as a reference for the cancer type. The input 
files must include all information on the chromosomes, 
coordinates and nucleotide changes. The genes that are 
stated as a driver should consist of tumor suppressor genes 
where loss of function is detected and oncogenes which 
gain of function is likely to be occurred in certain variants. 
In this analysis, consensus results from both tools were 
chosen and considered as highly confidence predicted 
driver genes (HCDG) (Figure 1).
PATHWAY ANALYSIS
KEGG MAPPER in combination with the information 
obtained from the bibliomic search were applied in 
identifying all pathways related to the predicted driver 
genes (Figure 2). Pathway mapping was performed using 
relevant KEGG pathway as a template in mapping the genes 
and to visualize the pathways that are likely to be affected 
by the driver genes was done using Cytoscape ver 3.6.0. 
Gene symbol of unique driver genes were set as an input 
in KEGG Mapper and the results were downloaded in KGML 
format for visualization. 
RESULTS AND DISCUSSION
CANCER DRIVER GENES PREDICTION
The consensus predicted genes obtained from iCAGES and 
CGI were named as high confidence driver genes (HCDG). 
Forty-four HCDG were identified using our approach (Table 
1). With this approach too, we have identified some genes 
that previously have not been listed in TCGA COADREAD 
and CGC Colorectal cancer genes dataset and have not 
been previously reported to be associated with colorectal 
cancer. Those genes were NCOR2, STAG2, PTPN12, TSC2, 
MYH9, NCOR1, PTCH1, ATF2 and ERBB3. These genes are 
potential candidates for newly identified colorectal cancer 
driver genes. 
PATHWAYS ASSOCIATED WITH PREDICTED DRIVER GENES
Nonsynonymous variants that occurred at the exonic 
region were selected as an input for iCAGES and CGI. 
Predicted driver genes from both tools were named as 
HCDG (high confidence driver genes) and their respective 
pathways were identified from KEGG database and 
literature (Table 2).
FIGURE 1. Selection of high confidence driver genes (HCDG) 
was based on the consensus result by iCAGES and CGI
FIGURE 2. A flowchart for the prediction of colorectal cancer driver genes
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TABLE 1. Consensus predicted genes obtained from iCAGES and CGI methods are considered as highly confident driver genes (HCDG). 
Genes with bold characters are CRC driver genes listed in TCGA – COADREAD. Genes with * sign are listed in CGC as CRC driver genes
Patient ID C187 C194 C273 C373 C404 C414 C449 C474
Gene name
1 TP53*         
2 FBXW7*         
3 POLR2B*         
4 SRGAP3*         
5 SMC1A         
6 KRAS*         
7 ITSN1         
8 TCF7L2*         
9 CUL1         
10 ARID1A*         
11 BRAF*         
12 STAG2         
13 BMPR2         
14 MYH10         
15 ERCC2*         
16 CDH1*         
17 CHEK2*         
18 NOTCH2*         
19 SIN3A         
20 HDAC3         
21 CLTC*         
22 TCF4         
23 RAD54L         
24 PHOX2B*         
25 HLA-A         
26 NTRK1         
27 ERBB3         
28 ATF2         
29 PTCH1         
30 NCOR1         
31 MYH9         
32 TSC2         
33 ERBB4         
34 PTPN12         
35 KLF5         
36 TSC1         
37 SPTAN1         
38 HGF         
39 HSP90AB1         
40 WNT5A         
41 MAP3K1         
42 RAX         
43 CDC27         
44 NCOR2         
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TABLE 2. List of predicted potential driver genes, their involvement in cellular pathways and previous reports on their occurrence in 
various cancers. Genes with bold characters are CRC driver genes listed in TCGA – COADREAD. 
Genes with * sign are listed in CGC as CRC driver genes
Driver Genes Pathways Cancer types References
TP53* p53 signaling Colorectal cancer
Melanoma
Breast Cancer
(Petitjean et al. 2007) 
(Ragnarsson-Olding et al. 2002)
FBXW7*  - Colorectal cancer (Iwatsuki et al. 2010)
SRGAP3*  G-protein signaling Colorectal cancer
Gastric cancer
(Huang et al. 2015)
KRAS* Ras, PI3K-AKT, MAPK signaling Colorectal cancer
Bladder cancer
Non-small cell lung cancer
Breast Cancer
(Phipps et al. 2013)
(Tian et al. 2013)
TCF7L2* Wnt signaling Colorectal cancer (Slattery et al. 2009)
(Folsom et al. 2008)
ARID1A* Chromatin organization pathway Colorectal cancer
Pancreatic cancer
(Mathur et al. 2017)
(Waddell et al. 2015)
BRAF* MAPK Colorectal cancer
Melanoma
Glioma
(Davies et al. 2002)
(Fang & Richardson 2005)
(Chen et al. 2014)
ITSN1 RET Signaling Lung cancer (R. Wang et al. 2015)
CUL1 Cell cycle pathway Colorectal cancer (W. Wang et al. 2015)
BMPR2 Tgf-Beta signaling Colorectal cancer
Gastric cancer
(Kodach et al. 2008)
(Park et al. 2010)
MYH10  - Colorectal cancer (Park et al. 2010)
ERCC2* Nucleotide excision repair Breast Cancer
Ovary Cancer
(Rump et al. 2016)
CDH1*
CHEK2*
Cell cycle pathway
p53 signaling 
Gastric cancer
Breast cancer
(Rump et al. 2016)
(Apostolou & Papasotiriou 2017)
NOTCH2* Notch Signaling Oesophageal cancer
Leukemia 
(C. Wang et al.016)
(Lobry et al. 2011)
SIN3A Thyroid hormone signaling Breast cancer (Lewis et al. 2016)
HDAC3 Viral carcinogenesis Colorectal cancer
Liver Cancer
(Bhaskara et al. 2011)
(Barneda-Zahonero & Parra 2012)
CLTC* Lysosome Breast cancer
Renal cancer
(Yao et al. 2015)
(Argani et al. 2003)
TCF4 Wnt signaling Colorectal cancer (Kim et al. 2003)
RAD54L Homologous recombination Colorectal cancer
Ovary Cancer
prostate cancer
(Pelttari et al. 2012)
PHOX2B* Neural Crest Differentiation Neuroblastoma (Bachetti et al. 2010)
HLA-A  - Colorectal cancer (Menon et al. 2002)
NTRK1 PI3K-Akt signaling pathway Colorectal cancer (Créancier et al. 2015)
(Iacopetta et al. 2006)
ERBB3 MAPK Signaling Breast cancer
Ovarian cancer
prostate cancer
(Ma et al. 2014)
(Sithanandam & Anderson 2008)
ATF2 PI3K-Akt signaling Renal cell carcinoma
skin cancer
(Wu et al. 2016)
(Bhoumik et al. 2008)
continue
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Driver Genes Pathways Cancer types References
PTCH1
NCOR1
MYH9
TSC2
ERBB4
PTPN12
KLF5
TSC1
SPTAN1
HGF
HSP90AB1
WNT5A
Hedgehog signaling
Endocrine resistance signaling
regulation of cytoskeleton
p53 signaling pathway
MAPK signaling
 -
 -
mTOR signaling pathway
Tgf-Beta Signaling
MAPK signaling pathway 
PI3K-Akt signaling
Transcription AR nuclear signaling
gastric cancer
Thyroid cancer
Lung cancer
Breast cancer
Colon cancer
Liver cancer
Breast Cancer
Bladder cancer
Oral Cancer
Esophageal cancer
Gastrointestinal cancer
Breast Cancer
(X. De Wang et al. 2013)
(Fozzatti et al. 2013)
(Katono et al. 2015)
(Mehta et al. 2011)
(Williams et al. 2015)
(Luo & Lam 2013)
(Jia et al. 2016)
(Metha et al. 2011)
(Prasad et al. 2016)
(Ren et al. 2005)
(Moser et al. 2009)
(Prasad et al. 2016)
MAP3K1 MAPK signaling Prostate cancer
Gastric cancer
(Pham et al. 2013)
RAX  -  -  -
CDC27  Cell cycle pathway Colorectal cancer
Breast cancer
(Qiu et al. 2016)
(Qiu et al. 2016)
NCOR2
STAG2
Notch signaling 
Cell cycle pathway
Breast cancer
Bladder cancer
(Van Agthoven et al. 2009)
(Black 2014)
Continued TABLE 2
 A total of 21 pathways have been identified related to 
the predicted CRC driver genes (Table 3). The information 
on the pathways where these genes were involved were 
obtained from KEGG database and literature searching. 
The result has suggested the involvement of driver genes 
in dysregulating the multiple pathways causing to the 
colorectal cancer carcinogenesis. The highest number 
of pathways might be dysregulated by driver genes were 
found in patient C474, followed by patient C414 and 
patient C373. 
 P53 signaling pathway shows positive signal of 
perturbation that affects 7 out of 8 patients in this study. 
Genes TP53, CHEK2 and TSC2 are predicted to drive 
colorectal carcinogenesis and related with p53 signaling 
pathway. Gene TP53 activated by CHEK2, CHEK1 and 
ATM to regulate various cell activities, meanwhile, TSC2 
regulated by TP53 to inhibit mTOR signaling pathway 
(Figure 3). Activation of mTOR signaling pathway will 
lead to increase in cell proliferation (Harris & Levine 
2005; Li et al. 2015; Shao et al. 2001). 
 Driver gene NCOR1 was found in the endocrine 
resistance pathway were predicted to be dysregulated in 
six patients (C187, C194, C373, C404, C414, and C474). 
In normal condition, NCOR1 forms a complex with ESR1 
to inhibit the genes that involved in cell proliferation 
(Figure 4).
 Driver genes such as KRAS, NTRK1, ERBB3, ATF2, 
ERBB4, and HSP90AB1 were found in patient C273, 
C404, C414, C449, and C474 and they were involved 
in Phosphoinositide 3-kinase-AKT (PI3K-AKT) pathway 
(Figure 5). PI3K-AKT signaling pathway is involved in 
mechanisms of growth stimulation, increase cellular 
proliferation and reduce apoptosis. Crucial component 
in PI3K-AKT is AKT3 is linked with driver gene, TSC2 
regulator of mammalian target of rapamycin (mTOR) 
signaling pathway. mTOR signaling pathway has role in 
cell growth and proliferation. 
 MAPK signaling pathway was predicted as one of the 
highly dysregulated pathways in patient C273, C404, 
C414, C449, and C474. Three genes were involved in this 
pathway, i.e. BRAF, ERBB3, and MAP3K1. ERBB3 encodes 
a member of RTK (Receptor Tyrosine Kinase) and RTK 
activation initiates MAPK signaling pathway which then 
leads to the activation of another key signaling molecules 
i.e. Ras, which was encoded by KRAS gene. BRAF encodes 
for B-Raf protein; one of regulator sin MAPK-ERK 
signaling pathway that involved in cell proliferation 
and differentiation whilst MAP3K1 encodes for MEKK1 
protein which is a key regulator in the MAPK-JNK signaling 
pathway. MEKK1 regulates proliferation, differentiation 
and inflammation (Fang & Richardson 2005; Ma et al. 
2014). 
CONCLUSION
From this study, 44 unique driver genes have been 
predicted in eight Malaysian colorectal cancer patients 
through extensive customized bioinformatics analysis 
along with the identification of 21 unique pathways that 
were found to be related with those driver genes. Amongst 
the identified pathways, that potentially perturbed driven by 
mutation of regulators are p53 signaling, PI3K-AKT, MAPK 
and endocrine resistance were predicted to be potentially 
perturbed driven by the mutation of regulators. Prediction 
of cancer driver genes will give detailed insight on the 
mechanisms of cancer development and a crucial step for 
targeted therapy process. 
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TABLE 3. Type of pathways that were associated with driver genes in each patient
C187 C194 C273 C373 C404 C414 C449 C474
p53 signaling pathway         
PI3K-AKT signaling pathway         
Wnt Signaling pathway         
tgf-β signaling pathway         
G-protein signaling         
MAPK signaling pathway         
RET signaling pathway         
Chromatin Organization         
Nucleotide excision repair         
Cell cycle pathway         
Notch Signaling         
Thyroid hormone signaling         
Viral carcinogenesis         
Homologous recombination         
Neural Crest Differentiation         
Hedgehog Signaling Pathway         
Endocrine resistance         
Tight junction         
Regulation of cytoskeleton         
mTOR signaling pathway         
Transcription AR nuclear signaling         
FIGURE 3. The involvement of the predicted drivers TP53, CHEK2 and TSC2 in p53 signaling pathway
FIGURE 4. NCOR1 in endocrine resistance pathways
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